

[See the webpage for non-financial data \(ESG data\).](https://global.sawaiigroup.holdings/sustainability/esg/)
<https://global.sawaiigroup.holdings/sustainability/esg/>

Financial indicators

(Sawai Group Holdings Co., Ltd. and its subsidiaries)

	Japanese-GAAP →					IFRS →						
	FY2012	FY2013	FY2014	FY2015	FY2016	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022
EFor the fiscal year (Millions of yen)												
Net sales / Revenue	80,503	89,824	105,454	123,492	132,428	132,392	168,068	184,341	182,537	187,219	193,816	200,344
Cost of sales	42,511	48,353	60,048	71,858	80,309	80,548	98,628	109,442	109,037	114,785	127,164	137,711
Gross profit	37,992	41,471	45,406	51,634	52,119	51,844	69,440	74,899	73,500	72,434	66,652	62,633
Selling, general and administrative expenses / Selling, general and administrative expenses (including research and development expenses)	20,607	22,380	24,718	28,449	31,486	28,497	47,264	49,051	46,862	53,820	71,103	46,246
Operating income / Operating profit (loss)	17,385	19,091	20,688	23,185	20,633	22,943	22,209	25,798	26,793	18,888	(35,888)	16,984
Profit before income taxes / Profit (loss) before tax	18,098	18,990	20,298	23,092	19,871	22,757	20,251	25,666	26,497	18,460	(36,214)	16,789
Profit attributable to owners of parent / Profit (loss) attributable to owners of the Company	12,022	12,193	14,053	17,156	15,914	17,969	14,017	19,376	19,279	12,340	(28,269)	12,667
Research and development (R&D) expenses	4,551	5,170	6,110	8,019	10,208	7,238	14,533	16,671	13,487	13,883	24,413	16,090
Capital expenditures	4,599	7,353	13,251	17,775	16,194	18,839	16,807	10,709	18,173	21,124	23,344	27,141
Depreciation and amortization	3,793	4,989	5,863	7,044	8,645	8,520	14,239	16,280	17,954	18,291	17,045	17,683
At fiscal year-end (Millions of yen)												
Total assets	127,843	149,348	166,180	206,492	221,539	225,609	358,453	372,889	384,814	393,341	349,502	364,165
Inventories	29,529	39,182	44,663	55,668	61,777	61,924	65,217	63,449	75,460	79,120	85,853	101,805
Total current liabilities	30,105	39,097	42,209	50,078	54,876	57,668	74,579	72,826	82,715	80,452	88,840	85,154
Total long-term liabilities / Total non-current liabilities	36,258	8,949	11,572	30,692	29,063	26,704	81,433	76,861	68,413	72,139	60,579	66,272
Net assets / Total equity	61,480	101,302	112,399	125,722	137,600	141,237	202,441	223,204	233,686	240,750	200,083	212,738
Cash flows (Millions of yen)												
Net cash provided by operating activities / Cash flows from operating activities	12,256	13,422	12,112	19,975	20,628	23,270	28,472	42,923	30,256	31,857	34,310	13,026
Net cash used in investing activities / Cash flows from investing activities	(1,373)	(8,283)	(14,123)	(22,937)	(16,207)	(18,827)	(127,900)	(16,820)	(18,173)	(21,794)	(30,395)	(27,134)
Net cash provided by (used in) financing activities / Cash flows from financing activities	(10,970)	(178)	(922)	13,473	(6,740)	(6,761)	108,597	(9,513)	(12,747)	(11,991)	(11,262)	(1,267)
Cash and cash equivalents at end of year / Cash and cash equivalents at the end of the year	20,584	25,537	22,604	33,096	30,771	30,771	39,992	57,067	56,082	54,269	47,717	33,076
Financial indicators (%)												
Ratio of R&D expenses to sales / Ratio of research and development expenses to revenue	5.7	5.8	5.8	6.5	7.7	5.5	8.6	9.0	7.4	7.4	12.6	8.0
Return on equity / Return on equity attributable to owners of the Company	20.1	15.0	13.2	14.4	12.1	13.4	8.7	10.2	9.4	5.8	(13.8)	6.5
Shareholders' equity to total assets / Ratio of equity attributable to owners of the Company to total assets	48.0	67.8	67.6	60.8	62.0	62.6	50.6	53.4	54.6	55.5	54.4	55.4
Per share information (yen)												
Net income—basic / Basic earnings per share	386.71	365.18	382.26	465.57	431.65	487.38	360.49	442.62	440.37	281.80	(645.53)	289.25
Net income—diluted / Diluted earnings per share	318.17	330.41	381.85	465.25	431.39	487.08	360.26	442.32	440.00	281.51	(645.53)	288.60
Cash dividends applicable to period / Dividends per share	85.00	95.00	105.00	120.00	130.00	130.00	130.00	135.00	130.00	130.00	130.00	130.00
Net assets / Equity attributable to owners of the Company per share	2,027.15	2,755.29	3,053.29	3,405.20	3,722.90	3,830.84	4,143.15	4,551.50	4,796.40	4,984.51	4,340.32	4,604.67

Non-financial indicators

(unless specially noted, for Sawai Pharmaceutical)

	FY2012	FY2013	FY2014	FY2015	FY2016	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022
Sales volume (Billion tablets)	57	65	80	89	102	102	106	119	124	133	148	150
Production capacity (Billion tablets)	80	86	100	113	150	150	155	155	155	155	155	155
Number of new products launched	32	23	28	25	18	18	43	33	12	44	32	23
Number of patents held	9	14	19	21	23	23	26	31	36	37	42	45
Number of GMP audits	—	—	—	—	—	164	100	110	133	124	141	153
Number of employees (consolidated)	1,050	1,121	1,239	1,490	2,502	2,502	3,252	3,131	3,066	3,003	2,968	3,393
Number of female employees in managerial positions	7	9	10	10	11	11	14	15	15	15	17	18
Ratio of female employees in managerial positions (%)	4.1	4.8	5.2	4.5	4.5	4.5	5.5	6.0	6.1	5.8	6.6	6.9
Employee training expenses (Japan Sawai Group) (Millions of yen)	59	65	83	90	111	111	128	87	62	45	63	85
Employees who have received training (Japan Sawai Group)	305	323	418	596	660	660	579	654	600	4,038	2,840	4,034
Employees involved in production (Sawai Pharmaceutical, Medisa Shinyaku, and Kaken Shoyaku)	305	350	414	628	1,612	1,612	1,749	1,687	1,644	1,607	1,636	2,015
Employees involved in R&D (Sawai Pharmaceutical, Medisa Shinyaku, and Kaken Shoyaku)	150	167	185	209	230	230	246	257	251	246	253	295
Energy used (Japan Sawai Group) (Crude oil conversion kl)	11,953	17,931	20,473	26,781	30,914	30,914	31,948	32,336	31,015	30,130	30,452	40,629

Notes 1. If there are differences in representation between Japanese-GAAP and IFRS (voluntarily applied since fiscal 2017), the item is marked "Japan GAAP / IFRS."
 2. Capital expenditures are presented on a cash flow basis.
 3. As the Company split its common stock two for one on October 1, 2013, amounts per share for fiscal 2012 – 2013 were recalculated to reflect the share split.
 4. Dividend per share in fiscal 2018 included our 90th anniversary commemorative dividend of ¥5.